We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
26 result(s) found, displaying 1 to 10
-
Jul-2025Prescription medicine evaluationActive ingredient: donidalorsen.
-
Designation or determinationOrphan drug
-
Cancellation by sponsorRequested by Otsuka Australia Pharmaceutical Pty Ltd
-
Cancellation by sponsorRequested by Otsuka Australia Pharmaceutical Pty Ltd
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Decitabine and cedazuridine
-
Prescription medicine registrationActive ingredients: cedazuridine; decitabine.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 15 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 30 mg + 90 mg tablet blister composite pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 15 mg + 45 mg tablet blister composite pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 30 mg tablet blister pack.